Back

Pharmacodynamic effects of vorapaxar as an add-on antiplatelet therapy in patients with and without diabetes mellitus: the optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS)-5 study

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Evolving developments in anti-platelet therapy Antiplatelet Drugs ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Dominick Joseph Angiolillo

University of Florida College of Medicine – Jacksonville, Jacksonville (United States of America)

6 More presentations in this session

Presentation thumbnail
A randomized controlled trial evaluating outcome impact of cilostazol in patients with coronary artery disease and at a high risk of cardiovascular disease
Professor T. Chao (Taichung, TW)
Abstract
Presentation thumbnail
Effect of de-escalated switching dual antiplatelet therapy after acute myocardial infarction in patients undergoing percutaneous coronary intervention: real-world data from a nationwide cohort study
Doctor C. Hsu (Taipei, TW)
Abstract Slides
Presentation thumbnail
Predictors of DAPT use in patients beyond 1 year post myocardial infarction: Insights from the TIGRIS observational study
Doctor J. Russo (Ottawa, CA)
Abstract Slides
Presentation thumbnail
Comparing treatment recommendations for the DAPT and PRECISE-DAPT scores after percutaneous coronary intervention
Doctor R. Boudreau (Ottawa, CA)
Abstract Slides
Presentation thumbnail
Platelet inhibitory profiles of prasugrel versus ticagrelor in patients with CYP2C19 loss-of-function genotypes undergoing percutaneous coronary intervention: results of a randomized feasibility study
Professor D. Angiolillo (Jacksonville, US)
Abstract Slides

Access the full session

Session thumbnail
Evolving developments in anti-platelet therapy

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Parenteral antiplatelet agents: when should they be used?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources